Embrex Inc. said Wednesday that an unidentified U.S. poultryproducer has signed a six-month trial lease of its Inovojectautomated egg inoculation system.
Financial terms were not divulged. Inovoject injects 20,000 to30,000 fertile eggs per hour with either Embrex's OVOAC-HVTor OVOVAC-SB-1 vaccine for Marek's disease, a viral disease ofpoultry.
The Research Triangle, N.C., company's system replaces post-hatch manual vaccination of day-old chicks with in ovovaccination on the 18th day of a broiler egg's 21-dayincubation period. All 6.5 billion broiler chickens raisedannually in the U.S. are vaccinated against Marek's.
The stock (NASDAQ:EMBX) gained 50 cents to $6.75.
(c) 1997 American Health Consultants. All rights reserved.